Condition: Breast Cancers · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.
This description comes directly from the study's public registry record.
Qiang Liu, PhD · 86-13922251256 · liuqiang_sysu@163.com
Yudong Li, PhD · 86+15989295289 · 649046236@qq.com
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Guangdong Women and children Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
| Cancer Hospital of Shantou University Medical College | Shantou, Guangdong, China | Not Yet Recruiting |
| Guangxi Provincial Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Not Yet Recruiting |
| Hainan Central Hospital | Haikou, Hainan, China | Not Yet Recruiting |
| the First Affiliated Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | Not Yet Recruiting |
| Peking University Shenzhen Hospita | Shenzhen, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07095023